Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 4.15 | — | — | 15.27 | — | 2.63 | 0.55 | — | — | 3.20 | — | — | — | 3.20 | — | — | — | — | 7.31 | — | — |
| — | — | — | — | — | -17.9% | — | — | — | -0.2% | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.54 | 6.84 | 2.38 | 1.98 | 5.00 | 1.17 | 0.43 | 3.65 | 5.98 | 1.26 | 1.78 | 0.51 | 8.48 | 0.46 | — | 0.71 | 0.48 | 5.40 | 2.46 | — | 21.66 |
| — | +485.9% | +457.8% | -45.8% | -16.5% | -7.7% | -76.0% | +615.9% | -29.5% | +177.4% | — | -28.5% | +1650.0% | -91.6% | — | — | -97.8% | -59.1% | -66.8% | — | +104.0% | |
| P/B Ratio | — | — | — | — | — | 29.67 | — | — | — | — | — | — | — | — | — | — | — | — | 91.00 | — | 33.59 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +614.1% | — | -46.4% | |
| P/FCF | — | — | — | — | 3.33 | — | — | — | — | 1.69 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 2.95 | — | — | 11.20 | — | 2.41 | 0.53 | — | — | 2.40 | — | — | — | 1.78 | — | — | — | — | 5.57 | — | — |
| — | — | — | — | — | +0.4% | — | — | — | +34.9% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 3.09 | — | — | 12.34 | — | 2.41 | 0.53 | — | — | 2.45 | — | — | — | 1.91 | — | — | — | — | 5.71 | — | — |
| — | — | — | — | — | -1.4% | — | — | — | +28.1% | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.7% | 74.9% | 78.0% | 82.9% | 69.5% | 94.1% | 97.9% | 58.5% | 28.3% | 88.9% | 48.0% | 48.9% | -348.4% | 86.9% | 630.3% | 36.8% | 40.8% | -45.8% | 97.5% | 100.0% | 100.0% |
| — | -20.4% | -20.3% | +41.7% | +145.8% | +5.8% | +103.9% | +19.6% | +108.1% | +2.3% | -92.4% | +32.7% | -953.1% | +289.7% | +546.5% | -63.2% | -59.2% | -145.8% | -2.5% | 0.0% | 0.0% | |
| Operating Margin | 50.1% | -96.8% | -11.1% | 14.3% | -252.7% | 44.2% | 77.3% | -148.4% | -158.6% | 38.7% | -147.8% | -63.0% | -569.4% | 13.1% | 4865.7% | -84.7% | -17.3% | -259.8% | 34.6% | 113.6% | -171.7% |
| — | -319.2% | -114.3% | +109.6% | -59.4% | +14.0% | +152.3% | -135.6% | +72.1% | +196.6% | -103.0% | +25.6% | -3188.5% | +105.0% | +13957.6% | -174.6% | +89.9% | -123.8% | +174.2% | +273.7% | -39.0% | |
| Net Margin | 39.2% | -94.2% | -6.8% | 11.9% | -287.3% | 44.5% | 77.8% | -91.8% | -143.5% | 39.1% | -157.2% | -61.2% | -592.7% | 13.7% | 4572.3% | -63.3% | -23.0% | -274.6% | 33.6% | 116.5% | -180.3% |
| — | -311.5% | -108.7% | +113.0% | -100.2% | +13.9% | +149.5% | -49.9% | +75.8% | +186.0% | -103.4% | +3.3% | -2482.2% | +105.0% | +13491.9% | -154.4% | +87.3% | -132.2% | +167.5% | +283.5% | -43.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | 283.1% | — | — | — | — | — | — | — | — | — | — | — | — | 311.4% | -1543.4% | -53.4% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +1264.9% | -3088.5% | +60.6% | |
| ROA | 32.2% | -5.3% | -0.9% | 1.5% | -16.1% | 8.1% | 36.4% | -5.0% | -6.9% | 10.2% | -9.4% | -10.3% | -7.8% | 3.6% | -15.5% | -8.1% | -6.9% | -18.7% | 7.5% | -32.9% | -12.1% |
| — | -165.9% | -102.4% | +130.0% | -134.1% | -20.9% | +488.2% | +52.1% | +12.2% | +184.8% | +39.4% | -28.2% | -13.5% | +119.2% | -305.7% | +75.5% | +43.2% | -42.2% | +170.7% | -134.1% | +42.3% | |
| ROIC | — | — | — | — | — | 640.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 6.07 | — | — | — | — | — | — | — | — | — | — | — | — | 6.74 | — | 0.93 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +1422.5% | — | -77.6% | |
| Debt / EBITDA | 0.42 | — | — | 9.52 | — | 2.02 | 0.44 | — | — | 1.36 | — | — | — | 3.04 | — | — | — | — | 2.04 | — | — |
| — | — | — | — | — | +48.9% | — | — | — | -55.4% | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.13 | 2.33 | 2.48 | 2.13 | 2.27 | 2.36 | 2.06 | 0.98 | 0.93 | 1.04 | 0.90 | 0.70 | 0.69 | 0.71 | 0.51 | 0.69 | 1.06 | 0.99 | 1.04 | 0.90 | 1.24 |
| — | -1.3% | +20.8% | +117.5% | +142.6% | +127.3% | +127.5% | +39.8% | +36.3% | +47.1% | +78.6% | +1.0% | -35.0% | -28.7% | -51.3% | -23.2% | -14.9% | -30.5% | -44.2% | -58.1% | -55.8% | |
| Quick Ratio | 2.10 | 2.30 | 2.45 | 2.10 | 2.24 | 2.34 | 2.03 | 0.97 | 0.93 | 1.03 | 0.88 | 0.67 | 0.64 | 0.69 | 0.49 | 0.68 | 1.01 | 0.87 | 0.99 | 0.90 | 1.24 |
| — | -1.5% | +20.6% | +116.6% | +141.1% | +126.5% | +129.8% | +44.0% | +45.3% | +49.1% | +81.1% | -0.5% | -36.5% | -20.7% | -50.7% | -24.9% | -18.9% | -38.9% | -46.7% | -58.1% | -55.8% | |
| Interest Coverage | 20.61 | -8.08 | -0.74 | 4.07 | -36.04 | 20.47 | 91.83 | -8.70 | -27.88 | 40.73 | -34.34 | -41.92 | -44.99 | 19.52 | -66.82 | -39.10 | -38.85 | -80.66 | 43.26 | -160.41 | -60.06 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NVAX stock.
Novavax, Inc.'s current P/E is 4.2x. The average P/E over the last 1 quarters is 15.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Novavax, Inc.'s current operating margin is 50.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Novavax, Inc.'s business trajectory between earnings reports.